This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

36/100

✓ Peer-reviewed alzhub usefulness score 36 out of 100. Biomarkers

Topic: Amyloid, tau and blood-test diagnosis

Here the current and emerging roles of brain positron emission tomography (PET) in Alzheimer's disease (AD) in the era of anti-amyloid-β antibody therapy, with a focus on clinical applications, methodological considerations, and future perspectives were reviewed. A narrative review of the literature on PET imaging in AD, including FDG-PET, amyloid PET, and tau PET, was conducted with particular emphasis on their clinical utility in diagnosis, and disease monitoring. Relevant guidelines, including appropriate use criteria and Japanese clinical guidelines, were also reviewed. FDG-PET provides valuable information for the differential diagnosis of neurodegenerative dementias based on characteristic hypometabolic patterns, although its role remains supportive due to the lack of direct assessment of molecular pathology. Amyloid PET enables noninvasive visualization of cerebral amyloid-β deposition and has become essential for confirming eligibility for anti-amyloid therapies. Standardized use criteria and interpretation guidelines are critical for appropriate clinical implementation. Quantitative approaches, such as standardized uptake value ratios (SUVRs) and the Centiloid scale, improve comparability across studies and institutions. Tau PET reflects neurofibrillary pathology and correlates with disease severity and progression, with increasing relevance for patient stratification. In addition, recent advances in high-resolution dedicated brain PET systems and artificial intelligence-based image analysis are expected to enhance diagnostic performance and workflow efficiency. In the era of disease-modifying therapy, brain PET imaging has become integral to the clinical management of AD. Amyloid PET is indispensable for treatment eligibility, while tau PET provides complementary information on disease stage and prognosis. Ongoing technological and methodological advancements will further expand the role of PET imaging in precision medicine for dementia.

Key findings

Tau PET reflects neurofibrillary pathology and correlates with disease severity and progression, with increasing relevance for patient stratification.
In addition, recent advances in high-resolution dedicated brain PET systems and artificial intelligence-based image analysis are expected to enhance diagnostic performance and workflow efficiency.
In the era of disease-modifying therapy, brain PET imaging has become integral to the clinical management of AD.
Amyloid PET is indispensable for treatment eligibility, while tau PET provides complementary information on disease stage and prognosis.
Ongoing technological and methodological advancements will further expand the role of PET imaging in precision medicine for dementia.

Why it matters

This review describes how amyloid PET is essential for confirming eligibility for anti-amyloid therapies, tau PET reflects neurofibrillary pathology and disease severity, and FDG PET supports differential diagnosis. It is about imaging's role in diagnosis and monitoring, not a treatment or cure.

New to this subject? Start with our plain-English guide: Blood tests & biomarkers →

Study details

Study designnarrative review
Evidence strengthLow

How this study scored 36/100

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it.

Component	Points	Why
Journal tier	7 / 10	Tier 3 — peer-reviewed journal (Japanese Journal of Radiology)
Journal's citation record	0 / 4	Japanese Journal of Radiology: journal h-index 59 (OpenAlex, 2026-10-29)
Study design	0 / 12	Design recorded as “narrative review”, which our rubric does not rank (not stated in the record — scored 0)
Strength of evidence	1 / 5	Rated “low” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	5 / 5	2026 — within 1 year(s) of the newest study here
Sample size	0 / 4	Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported	0 / 3	No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people	0 / 3	Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomised / blinded	0 / 2	No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited	1 / 7	Cited 2 times (OpenAlex, 2026-10-10)
Citations per year	1 / 5	1.0 citations a year over 2 year(s) since 2026
Impact for its field and year	4 / 6	Cited 9.5× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here	0 / 6	No other study in this library cites it
Still being cited	0 / 4	Cited 2 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record	3 / 4	Last-listed author Kazunari Ishii: h-index 53 (OpenAlex, whole career)
Institution's track record	0 / 3	Kobe University: institution h-index 619 (OpenAlex)
Multi-centre collaboration	0 / 3	OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete)
Indexed in PubMed	2 / 2	Indexed in PubMed (PMID 42033565)
Free to read	2 / 2	Free to read
Total	36 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

APA 7th

Ishii, K. (2026). Brain PET in the era of anti-amyloid-β antibody therapy for Alzheimer disease. Japanese Journal of Radiology. https://doi.org/10.1007/s11604-026-01998-4

Vancouver

Ishii K. Brain PET in the era of anti-amyloid-β antibody therapy for Alzheimer disease. Japanese Journal of Radiology. 2026. doi:10.1007/s11604-026-01998-4. PMID: 42033565.

BibTeX

@article{ishii2026-42033565,
  author  = {Ishii, Kazunari},
  title   = {{Brain PET in the era of anti-amyloid-β antibody therapy for Alzheimer disease}},
  journal = {Japanese Journal of Radiology},
  year    = {2026},
  doi     = {10.1007/s11604-026-01998-4},
  pmid    = {42033565},
  url     = {https://doi.org/10.1007/s11604-026-01998-4}
}

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 13.

Related studies in Biomarkers

Similar studies

More on Biomarkers

See all studies in Biomarkers →